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ABSTRAK
Latar belakang: glukosamin-kondroitin sulfate sering digunakan untuk mencegah degenerasi lutut lebih 
lanjut pada osteoartritis (OA). Metilsulfonilmetan (MSM) adalah suplemen yang mengandung belerang organik 
dan juga dilaporkan memperlambat progresifitas kerusakan anatomis pada OA lutut. MSM sering dikombinasikan 
dengan glukosamin dan kondroitin sulfat. Namun, masih terdapat kontroversi apakah glucosamin-kondroitin 
sulfat atau kombinasinya dengan methylsulfonylmethane secara efektif dapat mengurangi rasa sakit pada OA. 
Penelitian ini bertujuan membandingkan perbaikan klinis glukosamin-kondroitin sulfat (GK), glukosamin-
kondroitin sulfat-metilsulfonilmetan (MSM) (GKM) dan plasebo pada pasien osteoartritis derajat Kellgren-
Lawrence I dan II. Metode: suatu uji klinis acak tersamar ganda dilakukan pada 147 pasien dengan OA lutut 
derajat Kellgren-Lawrence I atau II. Subyek dibagi menjadi 3 kelompok, dengan metode randomisasi blok 
permutasi, yaitu kelompok GK (n=49), GKM (n=50) dan plasebo (n=48). Kelompok GK mendapat 1500 
mg glukosamin + 1200 mg kondroitin sulfat + 500 mg sakarumlaktis; kelompok GKM mendapat 1500 mg 
glukosamin + 1200 mg kondroitin sulfat + 500 mg MSM; kelompok plasebo menerima 3 kapsul yang serupa 
berisi sakarum laktis. Obat-obatan ini diberikan sekali sehari selama 3 bulan berturut-turut. Skor VAS dan 
WOMAC dinilai sebelum pemberian terapi, kemudian pada minggu ke 4, 8 dan 12. Hasil: pada analisa statistik 
ditemukan perbedaan signifikan pada minggu ke 12, dimana kelompok GK pada skor WOMAC berbeda signifikan 
dibandingkan dengan GKM dan plasebo (p=0,005), sedangkan GKM pada skor VAS berbeda signifikan 
dibandingkan dengan GK dan plasebo (p=0,001). Pada analisis lebih lanjut ditemukan bahwa terdapat perbedaan 
signifikan pada kelompok GKM dan GM pada skor VAS. Efektivitas pemberian per 4 minggunya ditemukan 
berbeda bermakna pada kelompok GKM dan plasebo (p<0,005). Kesimpulan: kombinasi glukosamin-kondroitin 
sulfat-metilsulonilmetan menunjukkan manfaat klinis yang lebih baik untuk pasien OA sendi lutut Kellgren-
Lawrence derajat I dan II dibandingkan dengan GK dan plasebo. Sedangkan suplemen GK secara umum tidak 
menunjukkan manfaat klinis yang lebih baik pada pasien OA sendi lutut derajat Kellgren Lawrence I-II.
Kata kunci: glukosamin, kondroitin sulfat, metilsulfonilmetan, osteoartritis.
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ABSTRACT
Background: Glucosamine, chondroitinsulfate are frequently used to prevent further joint degeneration in 
osteoarthritis (OA). Methylsulfonylmethane (MSM) is a supplement containing organic sulphur and also reported 
to slow anatomical joint progressivity in the knee OA. The MSM is often combined with glucosamine and chondroitin 
sulfate. However, there are controversies whether glucosamine-chondroitin sulfate or their combination with 
methylsulfonylmethane could effectively reduce pain in OA. This study is aimed to compare clinical outcome 
of glucosamine-chondroitin sulfate (GC), glucosamine-chondroitin sulfate-methylsulfonylmethane (GCM), 
and placebo in patients with knee osteoarthritis (OA) Kellgren-Lawrence grade I-II. Methods: a double blind, 
randomized controlled clinical trial was conducted on 147 patients with knee OA Kellgren-Lawrence grade 
I-II. Patients were allocated by permuted block randomization into three groups: GC (n=49), GCM (n=50), 
or placebo (n=48) groups. GC group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate + 
500 mg of saccharumlactis; GCM group received 1500 mg of glucosamine + 1200 mg of chondroitin sulfate 
+ 500 mg of MSM; while placebo group received three matching capsules of saccharumlactis. The drugs were 
administered once daily for 3 consecutive months VAS and WOMAC scores were measured before treatment, 
then at 4th, 8th and 12th week after treatment. Results: on statistical analysis it was found that at the 12th week, 
there are significant difference between three treatment groups on the WOMAC score (p=0.03) and on the VAS 
score (p=0.004). When analyzed between weeks, GCM treatment group was found statistically significant on 
WOMAC score (p=0.01) and VAS score (p<0.001). Comparing the score difference between weeks, WOMAC 
score analysis showed significant difference between GC, GCM, and placebo in week 4 (p=0.049) and week 12 
(p=0.01). In addition, VAS score also showed significant difference between groups in week 8 (p=0.006) and 
week 12 (p<0.001). Conclusion: combination of glucosamine-chondroitinsulfate-methylsulfonylmethane showed 
clinical benefit for patients with knee OA Kellgren-Lawrence grade I-II compared with GC and placebo. GC 
did not make clinical improvement in overall groups of patients with knee OA Kellgren Lawrence grade I-II.
Keywords: Glucosamine, chondroitin sulfate, methylsufonylmethane, osteoarthritis.
INTRODUCTION
Osteoarthritis (OA) is one of the most 
common degenerative joint disorders in the 
knee which prevalence increases dramatically 
along with the rise of life expectancy. Many 
studies were performed to obtain effective 
and safe regimens to prevent or even reverse 
the degenerative process in osteoarthritis. 
Progressive destruction of articular cartilage can 
result in swelling, pain, and disability.1,2
Common drugs for OA treatment are 
analgetics and non-steroidal anti-inflammatory 
drugs (NSAIDs) which have a long term 
side effects. Therefore, there is still an 
unmet need for  alternative therapies for OA 
which are efficacious and well-tolerated. 
Combinations of glucosamine-chondroitin 
sulfate (GC) or glucosamine-chondroitinsulfate-
methylsulfonylmethane (MSM) (GCM) are 
considered as food supplements according to 
Food and Drug Administration (FDA). Although 
many controversies arise about the use, it is still 
commonly used in daily clinical practice.2,3
Glucosamine, chondroitinsulfate are 
frequently used to prevent further joint 
degeneration in OA. Methylsulfonylmethane 
(MSM) is a supplement containing organic 
sulphur and also reported to slow anatomical joint 
progressivity in the knee OA. The MSM is often 
combined with glucosamine and chondroitin 
sulfate. However, there are controversies 
whether glucosamine-chondroitin sulfate or 
their combination with methylsulfonylmethane 
could effectively reduce pain in OA.3-5 This study 
compared clinical outcome of glucosamine-
chondroitine sulfate (GC) and glucosamine-
chondroitine sulfate-MSM (GCM) treatment 
based on WOMAC and VAS score assessment in 
patients with first and second grade of (Kellgren-
Lawrence) knee OA.
METHODS
This was a double blind randomized 
controlled clinical trial on 147 patients with 
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first and second grade (Kellgren-Lawrence) of 
knee OA. The diagnosis of knee osteoarthritis 
was based on clinical examination and X-ray 
imaging. Grading of the disease was done using 
antero-posterior knee X-ray and determined 
by using Kellgren Lawrence grading score. 
Eligibility criteria was symptomatic knee OA 
according to American College of Rheumatology 
(ACR)6 for at least 6 months, confirmed and 
grading by radiographic imaging according to 
Kellgren Lawrence score.7 Exclusion criteria 
were patients with inflammatory arthritis and 
other types of arthritis, patients with diabetes 
mellitus, patients who have history of recent knee 
injury, patients who lack of ability to perform or 
comply with treatment procedure.
Subjects were allocated by permuted block 
randomization into three groups, glucosamine-
chondroitinsulfate (GC; n=49), glucosamine-
chondroitin sulfate-MSM (GCM; n=48), 
and placebo (n=50); and sampling was done 
consecutively. The GC group received 1500 
mg of glucosamine + 1200 mg of chondroitin 
sulfate + 500 mg of saccharumlactis; GCM 
group received 1500 mg of glucosamine + 1200 
mg of chondroitin sulfate + 500 mg of MSM; 
while placebo group received three matching 
capsules of saccharum lactis. These drugs were 
administered once daily for three consecutive 
months. Treatment outcome was measured by 
Western Ontario and McMaster University 
Osteoarthritis Index (WOMAC)8 andVisual 
Analog Scale (VAS)9 scores.WOMAC score 
is questionnaire to assess pain, stiffness and 
physical function in OA patients. Evaluation was 
done at the baseline, then at the 4th, 8th, and 12th 
week after treatment.
The distribution of WOMAC and VAS 
groups at 4th, 8th, and 12th week was analyzed 
using one-sample Kolmogorov-Smirnov test 
using SPSS. For groups with normal distribution, 
ANOVA test was performed to compare with the 
baseline, followed by posthoc Bonferonni test 
for subgroup analysis. For groups with abnormal 
data distribution, Kruskall-Wallis test were 
performed, followed by Mann-Whitney test for 
subgroup analysis. Independent t-test were also 
used to analyse the mean and median difference 
between GCM and GC groups for each week.
Additionally, the data distribution of GCM, GC, 
and placebo group at the 4th, 8th, and 12th week 
were analysed. Afterward, paired t-test test were 
Figure 1. Subject flowchart
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performed to compare the normally distributed 
groups with the baseline based on WOMAC and 
VAS scores, while Wilcoxon test were performed 
at the abnormally distributed groups.The p-value 
less than 0.05 were considered as significant.
The study adheres to the guidelines of the 
ethical review process issued by the Health 
Research Ethical Committee of FKUI/RSCM. 
Ethical clearance has been issued for the study 
in February 2013(78/H2.F1/ETIK/2013).
RESULTS
A total of 160 patients were screened and 
13 patients were excluded (5 patients were 
diagnosed rheumatoid arthritis, 3 patients had 
history of traumatic knee injury, 2 patients had 
diabetes mellitus, and 3 patients could not comply 
with the treatment and evaluation procedures). 
Thus, 147 patients were eligible for this study and 
underwent randomization (Figure 1). From 147 
patients, the mean age of patients was 61 years, 
and 67.3% of them were woman. Baseline VAS 
score were roughly similar between the GCM 
(4 SD 1.6), GC (3.8 SD 1.6), and placebo group 
(3.54 SD 1.5). Baseline WOMAC score was 
equal in the GCM (34.16 SD 15.9) and placebo 
(34.65 SD 7.5) groups, but it was slightly lower 
in the GC group (27.73 SD 9.3). This difference 
was not statistically significant (p>0.05). There 
was a slight predominance of female prevalence 
in the male to female ratio (1:2) from the 
samples. There was also no significant difference 
between the number of patients with unilateral 
and bilateral knee OA and also the number of 
patients with first grade and second grade of knee 
OA among those three groups (Table 1).
Table 2 presented the result of between 
groups analysis, either between weeks or 
between treatment groups. At the 12th week, 
there was significant difference between three 
treatment groups on the WOMAC score (p=0.03) 
and on the VAS score (p=0.004). When analyzed 
between weeks, GCM treatment group was 
found statistically significant on WOMAC score 
(p=0.01) and VAS score (p<0.001).
On further subgroup analysis, GC treatment 
group was found statistically significant at the 
12th week compared to placebo group (p=0.005). 
While on the 12th week, GCM treatment group 
Table 1. Baseline characteristics of patients
GCM 
(n=50)
GC  
(n=49)
Placebo 
(n=48)
Mean of age 
(years)
58.3 (10.4) 60.9 (9.3) 62.8 (7.5)
Gender (%)
 - Male 22 34.7 58.3
 - Female 78 65.3 41.7
WOMAC, 
mean (SD)
34.16 (15.9) 27.73 (9.3) 34.65 (14.65)
VAS, mean 
(SD)
4.04 (1.6) 3.82 (1.6) 3.54 (1.5)
Osteoarthritis (%)
 - Unilateral 12.5 10.2 14
 - Bilateral 87.5 89.8 86
 - Grade 1 54 63.3 41.7
 - Grade 2 46 26.7 58.3
Table 2. Statistical analysis of WOMAC and VAS score
WOMAC GC GCM Placebo P-value
Week 0 27.73 (SD 17.08) 34.16 (SD 15.98) 34.65 (SD 14.65) 0.06a
Week 4 25.38 (SD 15.99) 29.04 (SD 16.09) 29.06 (SD 15.15) 0.41a
Week 8 24.43 (SD 15.97) 27.04 (SD 14.68) 28.85 (SD 13.98) 0.35a
Week 12 21.02 (SD 13.15) 22.04 (SD 11.34) 29.19 (SD 13.15) 0.03*a
P-value 0.12a 0.01*a 0.168a
VAS GC GCM Placebo P-value
Week 0 4.00 (1.00-8.00) 4.00 (2.00-9.00) 3.00 (0.00-7.00) 0.539k
Week 4 3.00 (0.00-10.00) 3.00(1.00-8.00) 3.00 (1.00-7.00) 0.898k
Week 8 3.00(1.00-8.00) 3.00(1.00-9.00) 3.00 (1.00-6.00) 0.100k
Week 12 3.00 (1.00-6.00) 3.00 (1.00-6.00) 3.00 (1.00-6.00) 0.004*k
P-value 0.598a <0.001*a 0.855a
*significant p<0.05; a) ANOVA test; k) Kruskall Wallis test
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was found significant compared to week 0 
(p<0.001). On the other hand, analysis of VAS 
score based on week of observation, at week 12 
GCM showed a significant difference compared 
to placebo group (p=0.001). Within GCM group 
itself, there was significant difference in week 12 
compared to week 0 (p<0.001).
Turning to score difference (Table 3), 
comparison of WOMAC score analysis showed 
significant difference between GC, GCM, and 
placebo in week 4 (p=0.049) and week 12 
(p=0.01). In addition, VAS score also showed 
significant difference between groups in week 8 
(p=0.006) and week 12 (p<0.001).
DISCUSSION
Glucosamine, chondroitin sulfate, and MSM 
are suggested to have an effect in decreasing pain 
and reducing further joint degradation in knee 
OA. However, there are debates on their efficacy 
as combination of glucosamine-chondroitin 
sulfate or glucosamine-chondroitin sulfate-MSM 
in osteoarthritis patients. This study was aimed 
to evaluate the efficacy of the combination of 
glucosamine and chondroitinsulfate with and 
without combination with MSM compared to 
placebo in grade I and II (Kellgren-Lawrence) 
of knee OA patients.
Baseline characteristic showed a slightly 
lower WOMAC score in the GC group, although 
it was not statistically significant; thus, it might 
present bias in the comparison of WOMAC score 
to other group. This difference was probably due 
to a slightly higher number of first degree knee 
OA patients in this group.
Generally, WOMAC scores at the 4th, 8th, 
and 12th week improved in all three groups. 
However, the significant scores was observed 
only at week 12 when compared to baseline. 
Comparing between the groups, GCM treatment 
groups showed significant on WOMAC score 
changes compared to placebo.Within group 
analysis also support the advantage of GCM 
on the 12th week on both scores. The sulfur 
contained in the MSM might also play role in 
replacing the loss of sulfur in the connective tissue 
during arthritis process.3-5 In OA, glucosamine, 
chondroitin sulfate, and MSM work slower,4,5 so 
that the difference of WOMAC and VAS score 
was more obvious in both interference groups 
at week 12.
However, the result of its WOMAC score 
in this study was not in line with GAIT study 
reporting that there was no significant difference 
of WOMAC pain and WOMAC function scores 
in knee OA patient compared to placebo.10 
Messier, et al.11 evaluated the efficacy of a daily 
dose of glucosamine 1500 mg and chondroitin 
sulfate 1200 mg with physical exercise compared 
to placebo with physical exercise in the physical 
function of 89 patients with knee OA for 12 
months. This study did not find any difference 
in the function, mobility, and pain between 
control and the treatment group even though 
they added 6 months period of treatment follow 
up. This significant decrease was possibly due 
to the baseline score difference in the GC group 
compared to placebo.12-15
Table 3. Statistical analysis of WOMAC and VAS score difference with week 0
WOMAC GC GCM Placebo P
Week 0 - - - -
Week 4 0.00 (-33 – 26) -4.50 (-30 – 35) -3.50 (-39 – 27) 0.049*k
Week 8 -3.74 (SD 13.17) -7.12 (SD 10.85) -5.79 (SD 11.44) 0.372a
Week 12 -4.00 (-53 – 16) -13.50 (-53 – 13) -1.00 (-41 – 23) 0.01*k
VAS GC GCM Placebo P
Week 0 - - - -
Week 4 0.00 (-4.00 – 3.00) 0.00 (-3.00 – 2.00) 0.00 (-3.00 – 4.00) 0.368k
Week 8 0.00 (-3.00 – 3.00) -1.00 (-4.00 – 3.00) 0.00 (-2.00 – 4.00) 0.006*k
Week 12 0.00 (-4.00 – 2.00) -1.00 (-5.00 – 1.00) 0.00 (-3.00 – 4.00) <0.001*k
*significant p<0.05; a) ANOVA test; k) Kruskall Wallis test
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Turning to pain perception, in our study the 
VAS score evaluation at week 4, 8, and 12 were 
also decreased in all three groups; however, the 
difference was also only statistically significant 
at week 12 in the GCM group compared to the 
placebo group, but not in the GC group. The 
significant decrease of VAS score in the GCM 
group might be related to the analgetic effect 
of MSM, and hence it has the ability to reduce 
pain.4,5 This finding was also in accordance with 
the previous research where GC worked slowly on 
the cartilage joint and hence the effect could only 
be observed at least 9 weeks after treatment.16,17 
This result was similar with previous study and 
strengthening the role of analgetic effect of MSM 
in decreasing VAS score.18,19
The decrease of VAS score at week 12 in the 
placebo group was comparable to that in the GC 
group. This finding was similar to the result of 
GAIT study stating that there was no difference 
of VAS score between GC and placebo group.10 
Similar result was also reported by Messier, et al.11 
although they have added 12 months of muscle 
exercise to get greater difference in function, 
mobility, and pain scores between placebo and 
GC group. The lack of treatment effect of GC 
might be due to the fact that the majority of oral 
chondroitin sulfate could not be hydrolyzed 
into monosaccharide in the digestive tract, and 
the fact that only a small amount of di-, oligo-, 
and polysaccharide are able to pass through the 
digestive process in the gut and absorbed to 
the blood. Due to this hydrolysis process, oral 
absorption of chondroitin was zero percent for 
high molecular weight chondroitinsulfate and 
8-12% for lower molecular weight chondroitin 
sulfate with more sulfate ratio. Apart from its 
size, chondroitin administered orally is only 
partially absorbed by the gut, hence only little 
amount of it may reach the joint.12-15 Our findings 
indicate that glucosamine-chondroitin sulfate 
was not effective in reducing joint pain in OA 
compared to placebo. Thus, this result should 
be considered when clinicians would like to 
recommend supplement containing glucosamine-
chondroitin sulfate to their OA patients. 
CONCLUSION
Combination of glucosamine-chondroitin 
sulfate-MSM showed a significant clinical 
improvement especially in terms of pain relief 
in patients with grade I-II Kellgren Lawrence 
of knee osteoarthritis (OA) compared with 
glucosamine-chondroitin sulfate and placebo. 
Glucosamine-chondroitin sulfate may bring 
significant clinical improvement in patients 
with grade I-II Kellgren Lawrence of knee OA 
compared to placebo; however, the supplement 
could not significantly reduce pain.
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